Goldman Sachs lowered the firm’s price target on Abbott (ABT) to $152 from $157 and keeps a Buy rating on the shares. After a year when fundamentals diverged from stock performance, 2026 should represent a return to normalized patterns where organic growth defines relative valuation, the analyst tells investors in a research note. The firm’s model does not include the pending acquisition of Exact Sciences (EXAS).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target raised to $144 from $142 at Evercore ISI
- Abbott price target raised to $169 from $162 at Barclays
- 3 Best Dividend Aristocrat Stocks to Buy in 2026
- Unusually active option classes on open December 30th
- Abbott Laboratories: Buy Rating Backed by Volt PFA-Driven Incremental Growth and Strengthening Electrophysiology Position